{"id":492,"date":"2026-02-28T10:20:20","date_gmt":"2026-02-28T10:20:20","guid":{"rendered":"https:\/\/heartcareforyou.in\/blog\/mitral-regurgitation-definition-clinical-context-and-cardiology-overview\/"},"modified":"2026-02-28T10:20:20","modified_gmt":"2026-02-28T10:20:20","slug":"mitral-regurgitation-definition-clinical-context-and-cardiology-overview","status":"publish","type":"post","link":"https:\/\/heartcareforyou.in\/blog\/mitral-regurgitation-definition-clinical-context-and-cardiology-overview\/","title":{"rendered":"Mitral Regurgitation: Definition, Clinical Context, and Cardiology Overview"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">Mitral Regurgitation Introduction (What it is)<\/h2>\n\n\n\n<p>Mitral Regurgitation is a condition where the mitral valve does not close fully.<br\/>\nThis allows blood to leak backward from the left ventricle into the left atrium.<br\/>\nIt is a type of valvular heart disease that affects blood flow and cardiac workload.<br\/>\nIt is commonly encountered during cardiac auscultation and echocardiography in cardiology clinics and hospitals.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Why Mitral Regurgitation matters in cardiology (Clinical relevance)<\/h2>\n\n\n\n<p>Mitral Regurgitation matters because it can be silent for years yet progressively change heart structure and function. When significant, it increases volume load on the left ventricle (LV) and left atrium (LA), which can contribute to heart failure symptoms, atrial fibrillation (AF), and pulmonary hypertension.<\/p>\n\n\n\n<p>Clinically, it is a frequent reason for cardiac imaging, longitudinal follow-up, and decisions about timing of valve intervention. Accurate characterization helps clinicians distinguish a primarily valve-driven problem (primary\/degenerative disease) from regurgitation driven by ventricular disease (secondary\/functional disease), because management strategies and expected responses can differ.<\/p>\n\n\n\n<p>From an education standpoint, Mitral Regurgitation links core cardiology concepts: valve anatomy, pressure\u2013volume physiology, murmurs, echocardiographic interpretation, and the relationship between symptoms and objective markers of cardiac remodeling. It is also a common clinical context for multidisciplinary decision-making involving cardiology, imaging, heart failure, and cardiac surgery or structural heart teams.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Classification \/ types \/ variants<\/h2>\n\n\n\n<p>Mitral Regurgitation is commonly classified by <strong>cause (etiology)<\/strong>, <strong>time course<\/strong>, and <strong>severity\/clinical stage<\/strong>.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">By mechanism and cause<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary (degenerative\/organic) Mitral Regurgitation<\/strong><\/li>\n<li>The problem is in the valve apparatus itself (leaflets, chordae tendineae, papillary muscles, annulus).<\/li>\n<li>Examples include myxomatous degeneration with prolapse, flail leaflet from chordal rupture, rheumatic changes, endocarditis-related leaflet damage, or annular calcification.<\/li>\n<li><strong>Secondary (functional) Mitral Regurgitation<\/strong><\/li>\n<li>The valve leaflets are often structurally near-normal, but the LV or LA geometry prevents effective closure.<\/li>\n<li>Common settings include ischemic cardiomyopathy, nonischemic dilated cardiomyopathy, and atrial functional Mitral Regurgitation related to LA dilation and annular enlargement (often in long-standing AF).<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">By time course<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Acute Mitral Regurgitation<\/strong><\/li>\n<li>Sudden onset regurgitation (for example, papillary muscle rupture after myocardial infarction, acute chordal rupture, or endocarditis).<\/li>\n<li>Hemodynamics can deteriorate quickly because the LA has not adapted.<\/li>\n<li><strong>Chronic Mitral Regurgitation<\/strong><\/li>\n<li>Gradual progression with compensatory LA and LV dilation.<\/li>\n<li>Symptoms may appear late, after remodeling or LV dysfunction develops.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">By severity and clinical stage<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Severity is commonly described as <strong>mild, moderate, or severe<\/strong> based on integrated clinical and imaging assessment (not a single measurement in isolation).<\/li>\n<li>Many teaching frameworks also describe stages from \u201cat risk\u201d to \u201csevere\/symptomatic,\u201d emphasizing that intervention decisions depend on severity plus physiology (LV size\/function, pulmonary pressures), symptoms, and mechanism. Specific staging systems and thresholds vary by guideline and clinical context.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Relevant anatomy &amp; physiology<\/h2>\n\n\n\n<p>The <strong>mitral valve<\/strong> sits between the LA and LV and normally allows one-way flow during diastole (LA \u2192 LV) and seals shut during systole (LV contraction). Competent closure depends on a coordinated \u201cvalve apparatus,\u201d including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Anterior and posterior leaflets<\/strong><\/li>\n<li><strong>Chordae tendineae<\/strong> (tethering cords)<\/li>\n<li><strong>Papillary muscles<\/strong> (anchoring structures in the LV)<\/li>\n<li><strong>Mitral annulus<\/strong> (fibrous ring that changes shape during the cardiac cycle)<\/li>\n<li><strong>LV geometry and contractile function<\/strong>, which influence coaptation (leaflet sealing)<\/li>\n<\/ul>\n\n\n\n<p>In normal systole, LV pressure rises well above LA pressure and the mitral valve closes, directing stroke volume into the aorta. In Mitral Regurgitation, some systolic flow is redirected back into the LA. This has key physiologic consequences:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The LA receives <strong>extra volume<\/strong> during systole, raising LA pressure and increasing pulmonary venous pressures in more severe or acute cases.<\/li>\n<li>The LV experiences <strong>volume overload<\/strong>, because regurgitated blood returns to the LV in the next diastole, increasing total LV filling.<\/li>\n<li>Over time, the LV may <strong>dilate<\/strong> to accommodate the extra volume, and the LA may enlarge, predisposing to AF.<\/li>\n<\/ul>\n\n\n\n<p>Because the regurgitant pathway offers a \u201clow-impedance\u201d outlet, the LV may eject more total volume while effective forward output (to the aorta) is reduced, especially when regurgitation is severe.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Pathophysiology or mechanism<\/h2>\n\n\n\n<p>At its core, Mitral Regurgitation results from <strong>inadequate leaflet coaptation<\/strong> (failure of the leaflets to meet and seal), which can occur through several mechanisms.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Primary (degenerative\/structural) mechanisms<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Leaflet prolapse<\/strong>: a leaflet bows back into the LA during systole, often due to myxomatous degeneration.<\/li>\n<li><strong>Flail leaflet<\/strong>: a leaflet tip loses chordal support (chordal rupture) and moves freely into the LA, often producing more dramatic regurgitation.<\/li>\n<li><strong>Restricted leaflet motion<\/strong>: rheumatic scarring or calcification can limit opening and closure.<\/li>\n<li><strong>Tissue destruction or perforation<\/strong>: infective endocarditis can damage leaflets or chordae.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Secondary (functional) mechanisms<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>LV dilation and remodeling<\/strong>: papillary muscles are displaced, tethering the leaflets and preventing full closure.<\/li>\n<li><strong>Ischemic remodeling<\/strong>: regional LV wall motion abnormalities can distort papillary muscle position and leaflet motion.<\/li>\n<li><strong>Annular dilation<\/strong>: enlargement and flattening of the annulus reduce leaflet coaptation; this can be driven by LV dilation or LA dilation (atrial functional Mitral Regurgitation).<\/li>\n<li><strong>Dyssynchrony<\/strong>: conduction abnormalities or pacing-related dyssynchrony can worsen functional regurgitation in some patients (impact varies by patient factors).<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Hemodynamic consequences over time<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chronic compensated phase<\/strong>: LA and LV adapt by dilating; many patients remain asymptomatic.<\/li>\n<li><strong>Decompensation<\/strong>: progressive LV dysfunction, rising LA pressure, pulmonary hypertension, and symptoms can develop.<\/li>\n<li><strong>Acute severe regurgitation<\/strong>: abrupt rise in LA and pulmonary venous pressures may cause pulmonary edema and hypotension because compensation has not occurred.<\/li>\n<\/ul>\n\n\n\n<p>The clinical impact depends on multiple interacting variables (regurgitant orifice characteristics, loading conditions, rhythm, ventricular function), and interpretation often varies by clinician and case.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Clinical presentation or indications<\/h2>\n\n\n\n<p>Common clinical scenarios where Mitral Regurgitation is considered or discovered include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Incidental murmur<\/strong> noted on routine exam, later evaluated by echocardiography  <\/li>\n<li><strong>Exertional dyspnea<\/strong> or reduced exercise tolerance, especially in chronic significant regurgitation  <\/li>\n<li><strong>Fatigue<\/strong> related to reduced forward cardiac output  <\/li>\n<li><strong>Palpitations<\/strong> or new atrial fibrillation, often in the context of LA enlargement  <\/li>\n<li><strong>Orthopnea or pulmonary edema<\/strong>, which can occur in acute severe Mitral Regurgitation or advanced chronic disease  <\/li>\n<li><strong>Post\u2013myocardial infarction deterioration<\/strong>, raising concern for papillary muscle dysfunction or rupture  <\/li>\n<li><strong>Fever with new murmur<\/strong> in suspected infective endocarditis (clinical context and testing guide probability)  <\/li>\n<li><strong>Heart failure evaluation<\/strong>, where functional Mitral Regurgitation may contribute to symptoms and prognosis  <\/li>\n<li><strong>Pre-procedure imaging workup<\/strong>, such as before valve intervention, coronary evaluation, or other cardiac surgery<\/li>\n<\/ul>\n\n\n\n<p>Physical exam findings may include a <strong>holosystolic murmur<\/strong> best heard at the apex, sometimes radiating to the axilla, and signs of volume overload in more advanced cases. Murmur intensity does not reliably equal severity; acute severe regurgitation may produce a softer murmur despite major hemodynamic impact.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Diagnostic evaluation &amp; interpretation<\/h2>\n\n\n\n<p>Diagnosis and characterization rely on integrating clinical assessment with imaging, most commonly echocardiography.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">History and physical examination<\/h3>\n\n\n\n<p>Clinicians typically assess:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Symptom pattern (exertional dyspnea, fatigue, orthopnea)<\/li>\n<li>Time course (sudden vs gradual onset)<\/li>\n<li>Potential causes (prior myocardial infarction, rheumatic disease history, known cardiomyopathy, infection risk factors)<\/li>\n<li>Signs of congestion (lung crackles, edema) and rhythm irregularity (AF)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Electrocardiogram (ECG)<\/h3>\n\n\n\n<p>ECG can show:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Atrial fibrillation or other atrial arrhythmias<\/li>\n<li>Evidence of LV hypertrophy or prior infarction patterns<\/li>\n<li>Nonspecific changes that support broader cardiac evaluation<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Chest imaging and laboratory tests<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chest X-ray<\/strong> may show LA enlargement, pulmonary congestion, or pleural effusions in more advanced cases (findings are not specific).<\/li>\n<li><strong>Laboratory testing<\/strong> is tailored to context (for example, heart failure assessment or infection evaluation). Protocols vary by patient factors and clinical setting.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Echocardiography (cornerstone test)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Transthoracic echocardiography (TTE)<\/strong> is the usual first-line test to confirm regurgitation, estimate severity, and define mechanism.<\/li>\n<li><strong>Transesophageal echocardiography (TEE)<\/strong> is often used when TTE images are limited, when detailed valve anatomy is needed, or when planning intervention.<\/li>\n<\/ul>\n\n\n\n<p>Clinicians evaluate:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Valve anatomy<\/strong> (prolapse, flail, restriction, calcification, perforation)<\/li>\n<li><strong>Regurgitation severity<\/strong> using an integrated approach (color Doppler jet characteristics, flow convergence, vena contracta appearance, pulmonary venous flow patterns, and overall hemodynamic context)<\/li>\n<li><strong>Chamber response<\/strong> (LA and LV size, LV systolic function)<\/li>\n<li><strong>Pulmonary pressures<\/strong> and right heart impact when relevant<\/li>\n<li><strong>Other valve lesions<\/strong> (tricuspid regurgitation, aortic valve disease), which may influence symptoms and planning<\/li>\n<\/ul>\n\n\n\n<p>Severity interpretation is not based on a single echocardiographic view or one number alone; loading conditions (blood pressure, volume status), heart rate, and rhythm can change observed regurgitation.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Additional imaging and testing (selected cases)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Cardiac magnetic resonance (CMR)<\/strong> can help quantify regurgitant volume and assess ventricular volumes and myocardial tissue characteristics, especially when echo findings are discordant or limited.<\/li>\n<li><strong>Exercise testing or stress echocardiography<\/strong> may clarify symptoms, functional capacity, pulmonary pressure response, or dynamic changes in regurgitation (use depends on clinical question and local practice).<\/li>\n<li><strong>Coronary evaluation<\/strong> may be relevant in ischemic disease or preoperative planning, depending on age, symptoms, and risk factors; the exact approach varies by protocol and patient factors.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Management overview (General approach)<\/h2>\n\n\n\n<p>Management is individualized and depends on <strong>severity<\/strong>, <strong>symptoms<\/strong>, <strong>LV function and remodeling<\/strong>, <strong>pulmonary pressures<\/strong>, <strong>rhythm<\/strong>, and <strong>etiology (primary vs secondary)<\/strong>. The overall goals are to reduce symptoms, prevent or limit adverse remodeling, and address the underlying mechanism when appropriate.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Conservative and monitoring approaches<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Many patients with mild or moderate Mitral Regurgitation are managed with <strong>clinical follow-up and periodic imaging<\/strong> to monitor severity and cardiac chamber response.<\/li>\n<li>Education commonly focuses on symptom recognition and adherence to follow-up plans, with intervals varying by clinician and case.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Medical therapy (supportive; mechanism-dependent)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>No medication \u201crepairs\u201d a structurally abnormal mitral valve.<\/li>\n<li>Medical therapy is often used to manage <strong>contributing conditions<\/strong> or <strong>consequences<\/strong>, such as:<\/li>\n<li>Heart failure therapies for LV dysfunction (particularly relevant in secondary Mitral Regurgitation)<\/li>\n<li>Rate\/rhythm strategies and anticoagulation decisions in atrial fibrillation (based on stroke-risk frameworks and patient factors)<\/li>\n<li>Blood pressure optimization, which can influence afterload and regurgitant fraction (approach varies)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Interventional and surgical options<\/h3>\n\n\n\n<p>When regurgitation is significant and physiology or symptoms warrant, options may include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mitral valve repair<\/strong><\/li>\n<li>Often preferred in many forms of primary degenerative disease when anatomy is suitable, because repair preserves native valve structure.<\/li>\n<li>Techniques can include leaflet repair, chordal procedures, and annuloplasty (ring support).<\/li>\n<li><strong>Mitral valve replacement<\/strong><\/li>\n<li>Considered when repair is not feasible or durable, or when pathology is complex.<\/li>\n<li><strong>Transcatheter therapies<\/strong><\/li>\n<li><strong>Transcatheter edge-to-edge repair (TEER)<\/strong> may be considered in selected patients with suitable anatomy and clinical profiles, particularly when surgical risk is high or when functional Mitral Regurgitation persists despite optimized medical therapy (selection criteria vary).<\/li>\n<li>Other transcatheter approaches exist or are evolving; availability and indications vary by center and regulatory environment.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Treating underlying causes<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>In <strong>secondary Mitral Regurgitation<\/strong>, addressing LV disease (ischemia, cardiomyopathy) and optimizing heart failure care is central, with valve intervention considered in selected cases.<\/li>\n<li>In <strong>acute severe Mitral Regurgitation<\/strong> due to mechanical disruption (for example, papillary muscle rupture), urgent stabilization and definitive intervention may be needed; the exact pathway is highly case-dependent.<\/li>\n<\/ul>\n\n\n\n<p>Because timing and choice of intervention depend on integrated imaging, symptoms, operative risk, and expected durability, decisions are often made with a multidisciplinary heart team. This article is educational and does not provide individualized treatment guidance.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Complications, risks, or limitations<\/h2>\n\n\n\n<p>Potential complications of Mitral Regurgitation (especially when significant) include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Heart failure<\/strong> due to chronic volume overload and eventual LV dysfunction  <\/li>\n<li><strong>Atrial fibrillation<\/strong> related to LA enlargement and pressure\/volume changes  <\/li>\n<li><strong>Pulmonary hypertension<\/strong> and secondary right-sided heart strain in advanced cases  <\/li>\n<li><strong>Reduced exercise tolerance<\/strong> and functional decline  <\/li>\n<li><strong>Thromboembolic risk<\/strong> primarily via atrial fibrillation or other coexisting conditions (risk varies by patient factors)  <\/li>\n<li><strong>Infective endocarditis<\/strong> risk can be increased in certain valve abnormalities; the degree of risk varies by underlying anatomy and history  <\/li>\n<li><strong>Hemodynamic instability in acute severe cases<\/strong>, including pulmonary edema and low forward output<\/li>\n<\/ul>\n\n\n\n<p>Limitations and context-dependent issues include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Echocardiographic grading variability<\/strong>, influenced by loading conditions and imaging windows  <\/li>\n<li><strong>Mixed valve disease<\/strong>, where coexisting stenosis or other valve lesions complicate interpretation  <\/li>\n<li><strong>Functional Mitral Regurgitation dynamics<\/strong>, where severity can change with blood pressure, volume status, ischemia, and rhythm  <\/li>\n<li><strong>Procedure-related risks<\/strong> (surgery or transcatheter intervention), which depend on patient comorbidities, anatomy, and local expertise<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Prognosis &amp; follow-up considerations<\/h2>\n\n\n\n<p>Prognosis in Mitral Regurgitation depends on more than the label alone. Important influences include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Severity and chronicity<\/strong> (mild vs significant; acute vs chronic)<\/li>\n<li><strong>Symptoms and functional capacity<\/strong><\/li>\n<li><strong>LV systolic function and dimensions<\/strong>, reflecting compensation versus decompensation<\/li>\n<li><strong>LA size and rhythm status<\/strong>, particularly development of atrial fibrillation<\/li>\n<li><strong>Pulmonary pressures<\/strong> and right heart involvement<\/li>\n<li><strong>Etiology<\/strong> (primary degenerative vs secondary functional), which affects treatment options and outcomes<\/li>\n<li><strong>Feasibility and durability of repair<\/strong> when intervention is considered<\/li>\n<li><strong>Comorbid conditions<\/strong>, such as coronary artery disease, chronic kidney disease, or chronic lung disease<\/li>\n<\/ul>\n\n\n\n<p>Follow-up generally centers on reassessing symptoms, physical findings, rhythm changes, and periodic imaging to detect progression or early signs of cardiac remodeling. The frequency and content of follow-up vary by clinician and case, and often depend on baseline severity and trajectory over time.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Mitral Regurgitation Common questions (FAQ)<\/h2>\n\n\n\n<p><strong>Q: What does Mitral Regurgitation mean in plain language?<\/strong><br\/>\nIt means the mitral valve leaks, so some blood flows backward into the left atrium when the left ventricle contracts. This can reduce efficient forward blood flow and increase the heart\u2019s workload over time. The impact depends on how much leakage is present and why it is happening.<\/p>\n\n\n\n<p><strong>Q: Is Mitral Regurgitation the same as mitral valve prolapse?<\/strong><br\/>\nNot exactly. Mitral valve prolapse is one possible cause, where a leaflet bows back into the left atrium during systole. Prolapse can occur with or without significant Mitral Regurgitation, and Mitral Regurgitation can occur without prolapse.<\/p>\n\n\n\n<p><strong>Q: How do clinicians determine if it is mild or severe?<\/strong><br\/>\nSeverity is usually determined by echocardiography using multiple features together rather than a single measurement. Clinicians also consider chamber size, pulmonary pressures, and how findings fit the overall clinical picture. Loading conditions and heart rhythm can affect what is seen on the day of testing.<\/p>\n\n\n\n<p><strong>Q: Can Mitral Regurgitation cause shortness of breath?<\/strong><br\/>\nYes. Significant regurgitation can raise pressures in the left atrium and pulmonary veins, contributing to exertional dyspnea and, in more advanced situations, congestion. Shortness of breath is not specific to Mitral Regurgitation, so clinicians typically evaluate other cardiac and non-cardiac causes as well.<\/p>\n\n\n\n<p><strong>Q: What tests are most commonly used to evaluate Mitral Regurgitation?<\/strong><br\/>\nTransthoracic echocardiography is the most common first test because it visualizes valve anatomy and estimates severity. Transesophageal echocardiography may be used for more detailed anatomy or procedural planning. Other tests (ECG, chest imaging, stress testing, CMR) are selected based on the clinical question.<\/p>\n\n\n\n<p><strong>Q: Does everyone with Mitral Regurgitation need a procedure or surgery?<\/strong><br\/>\nNo. Many people have mild regurgitation that is monitored over time without intervention. Procedures are considered when regurgitation is significant and associated with symptoms, cardiac remodeling, declining function, or specific high-risk features, with decisions varying by clinician and case.<\/p>\n\n\n\n<p><strong>Q: What is the difference between primary and secondary Mitral Regurgitation?<\/strong><br\/>\nPrimary Mitral Regurgitation is driven by a structural abnormality of the valve apparatus itself (leaflets, chordae, annulus). Secondary Mitral Regurgitation is driven by changes in the ventricle or atrium that prevent normal closure, often in the setting of cardiomyopathy or ischemic disease. This distinction helps guide management strategy.<\/p>\n\n\n\n<p><strong>Q: Can Mitral Regurgitation improve on its own?<\/strong><br\/>\nIt can change over time, and in some functional cases it may lessen if the underlying ventricular condition improves or loading conditions change. In degenerative structural disease, spontaneous improvement is less typical, though severity can still appear variable depending on hemodynamics and measurement conditions. Trends over time and mechanism matter.<\/p>\n\n\n\n<p><strong>Q: What follow-up is typical after a diagnosis?<\/strong><br\/>\nFollow-up commonly includes periodic clinical review and repeat echocardiography to monitor severity and heart chamber response. The interval depends on baseline severity, symptoms, and changes over time, and varies by protocol and patient factors. New symptoms or rhythm changes often prompt reassessment.<\/p>\n\n\n\n<p><strong>Q: Does Mitral Regurgitation affect returning to exercise, work, or daily activities?<\/strong><br\/>\nIt can, especially if symptoms develop or if regurgitation is significant enough to affect forward output or cause congestion. Many people remain active with mild disease, while others may notice limitations as severity progresses. Activity recommendations are individualized and depend on symptoms, rhythm, and overall cardiac function, so they vary by clinician and case.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mitral Regurgitation is a condition where the mitral valve does not close fully. This allows blood to leak backward from the left ventricle into the left atrium. It is a type of valvular heart disease that affects blood flow and cardiac workload. It is commonly encountered during cardiac auscultation and echocardiography in cardiology clinics and hospitals.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-492","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts\/492","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/comments?post=492"}],"version-history":[{"count":0,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/posts\/492\/revisions"}],"wp:attachment":[{"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/media?parent=492"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/categories?post=492"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/heartcareforyou.in\/blog\/wp-json\/wp\/v2\/tags?post=492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}